SCYNEXIS (NASDAQ:SCYX – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Thursday. SCYNEXIS Stock Up 8.6 % ...

Background: In adolescents and young females, abnormal vaginal discharge (AVD) is of prevalent concern. The syndromic therapy ...

Medically reviewed by Edmund Khoo, DDS Thrush, or oral candidiasis, is a fungal infection in your mouth and throat. It is ...

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S.

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted ...

Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the "Company" or "ZCT"), a FemTech medical device company revolutionizing ...

Discover how new global guidelines aim to combat the rising threat of Candida infections with updated treatments and ...

The new guidelines provide updated diagnostic and therapeutic strategies for both mucocutaneous and invasive candidiasis.

Diabetes, heart diseases and ovarian cancer can creep in without early warning signs. Doctor explains how to spot them.

In a study set to be published in Mycology, a research team led by Prof. Jianping Xu from McMaster University and researcher Jinyan Wu from Hainan Medical University presents new findings on Candida ...

But a closer look at the basic approach and assumptions undergirding this research, the inclusion of vaccine critics among ...

In summary, the application of genomics technologies has markedly advanced in-depth research on candidiasis, providing a theoretical framework for clinical management and guiding the development of ...